Cannabinoid (CB(1)), GABA(A) and GABA(B) receptor subunit changes in the globus pallidus in Huntington's disease.
about
Care and feeding of the endocannabinoid system: a systematic review of potential clinical interventions that upregulate the endocannabinoid system.Genetics and neuropathology of Huntington's diseaseThe endocannabinoid system as a target for the treatment of neurodegenerative disease.Temporal changes of CB1 cannabinoid receptor in the basal ganglia as a possible structure-specific plasticity process in 6-OHDA lesioned rats.Promising cannabinoid-based therapies for Parkinson's disease: motor symptoms to neuroprotectionCannabinoids and Dementia: A Review of Clinical and Preclinical Data.Complex relationships between cerebral blood flow and brain atrophy in early Huntington's disease.Elevated arteriolar cerebral blood volume in prodromal Huntington's disease.Dopamine and glutamate in Huntington's disease: A balancing act.Functional diversity on synaptic plasticity mediated by endocannabinoids.The endocannabinoid system: a putative role in neurodegenerative diseases.Cognitive interventions to enhance neural compensation in Huntington's disease.Clinical Endocannabinoid Deficiency Reconsidered: Current Research Supports the Theory in Migraine, Fibromyalgia, Irritable Bowel, and Other Treatment-Resistant Syndromes.The Complexity of Clinical Huntington's Disease: Developments in Molecular Genetics, Neuropathology and Neuroimaging Biomarkers.The role of the human globus pallidus in Huntington's disease.Endocannabinoid system in neurodegenerative disorders.Regulation of opioid and cannabinoid receptor genes in human neuroblastoma and T cells by the epigenetic modifiers trichostatin A and 5-aza-2'-deoxycytidine.Towards a Better Understanding of GABAergic Remodeling in Alzheimer's Disease.Bicuculline-induced chorea manifests in focal rather than globalized abnormalities in the activation of the external and internal globus pallidus.Globus pallidus degeneration and clinicopathological features of Huntington disease.Altered behavioral responses to gamma-aminobutyric acid pharmacological agents in a mouse model of Huntington's disease.GABAA and GABAB receptor subunit localization on neurochemically identified neurons of the human subthalamic nucleus.Disrupted striatal neuron inputs and outputs in Huntington's disease.Striatal Direct and Indirect Pathway Output Structures are Differentially Altered in Mouse Models of Huntington's Disease.Striatal input- and rate-dependent effects of muscarinic receptors on pallidal firing
P2860
Q21132308-6137F875-141E-4D77-AC10-CC91B7483DA0Q27023050-038381B6-C3CD-40AD-B55E-0B1C59CDD8EDQ34098196-A2480271-D51B-4B36-A172-64E6C3C5361CQ35014951-BC805D34-E2ED-4A04-BC68-344B8AAA117CQ35499568-766C7C86-F319-488E-8E15-54C8ED9B2A81Q36155898-AD7688AE-0994-4EEA-892C-D28963963AE2Q37207535-163BF784-30B3-46CB-BE34-E5883A23C4EBQ37325474-5FF56B88-93B0-45EB-89F6-DB3FD50E7947Q37734563-AA2D5C5D-C979-4CE8-97E8-966F04EC7429Q38056394-25616EAE-20D6-4010-B156-2D0DE58C05BAQ38223774-903E0F95-029B-4BB8-8907-17B36F15074BQ38430852-882F0497-63FD-4AFB-8298-D6853D8B3BD7Q38598509-39BB0F68-0D4F-4D89-9879-344F5E0DAFB1Q38663086-CE0A6E84-9999-458F-80B7-5F5A84D2030DQ38928744-DA11838D-EB83-4AC2-A2C3-72A0B18A73ADQ39368845-B64E3615-DBBC-4A6A-ADBE-78FA3B7DA492Q39409413-40180E60-811F-49CD-BCCB-11A9D80D3364Q41574564-238D215A-1136-4FC6-A636-C17039F6F234Q42473597-08FBF563-8898-4F41-B9C8-26B16BDD739EQ45295460-D315F09E-16F0-4F2C-921D-353F2AE923A9Q45303467-7E544ED9-DAC0-4B39-9710-B48687730BB9Q47926886-251D571F-3AC1-4E24-B876-7725AE194A4DQ52690256-D3A2EFBE-F8A7-476D-A865-4807A9799D37Q52691798-6059E7E3-C002-4811-AE77-C831B3B48FD8Q58914830-07077629-0B87-48DD-A0D9-54FCBE75AA61
P2860
Cannabinoid (CB(1)), GABA(A) and GABA(B) receptor subunit changes in the globus pallidus in Huntington's disease.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
2009年论文
@zh
2009年论文
@zh-cn
name
Cannabinoid (CB(1)), GABA(A) a ...... lidus in Huntington's disease.
@en
Cannabinoid (CB(1)), GABA(A) a ...... lidus in Huntington's disease.
@nl
type
label
Cannabinoid (CB(1)), GABA(A) a ...... lidus in Huntington's disease.
@en
Cannabinoid (CB(1)), GABA(A) a ...... lidus in Huntington's disease.
@nl
prefLabel
Cannabinoid (CB(1)), GABA(A) a ...... lidus in Huntington's disease.
@en
Cannabinoid (CB(1)), GABA(A) a ...... lidus in Huntington's disease.
@nl
P50
P921
P1476
Cannabinoid (CB(1)), GABA(A) a ...... llidus in Huntington's disease
@en
P2093
P304
P356
10.1016/J.JCHEMNEU.2009.02.001
P577
2009-02-21T00:00:00Z